While long-acting beta2-agonists (LABAs) and low to moderate doses of inhaled corticosteroids for asthma in pregnancy were not associated with an increased prevalence of adverse perinatal outcomes in a recent cohort study, there was a slight trend toward increased prevalence of low birthweight, premature birth, and small for gestational age infants when mothers were exposed to inhaled corticosteroids at high doses.
The offspring of women who receive inhaled glucocorticoid medications to treat asthma during pregnancy may have a significantly increased risk of endocrine and metabolic disorders, according to a population-based cohort study published in the American Journal of Respiratory and Critical Care Medicine.
Rates of asthma continue to rise in the general population, which translates to increased rates among women who are pregnant. When this happens, asthma not only affects the mother but the fetus as well. However, the specific effects are unclear. With that in mind, Dr Vanessa Murphy, postdoctoral research fellow school of medicine and public health at the University of Newcastle in Australia, and colleagues conducted a meta-analysis to determine if maternal asthma is associated with adverse perinatal outcomes.
Increases in the prevalence of asthma, especially in children, have raised concern in the medical community, resulting in research to find possible causes and to explore potential means of prevention. Recently there has been some evidence linking acetaminophen (known as paracetamol in New Zealand) use in pregnant women and subsequent increased risk for asthma in their offspring.
Children whose mothers used paracetamol during their pregnancy may have a slightly increased risk of childhood wheeze, according to a meta-analysis published in the April issue of Clinical & Experimental Allergy.
Maternal anemia during pregnancy is linked with wheezing and asthma in early childhood, according to a study published in the February issue of the Annals of Allergy, Asthma & Immunology.
The use of progestin-estrogen oral contraceptive pills (OCPs) in women prior to becoming pregnant does not appear to increase the risk of adverse respiratory outcomes in offspring, according to a study presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology, held from March 18 to 22 in San Francisco.
The U.S. Food and Drug Administration is warning that terbutaline administered by injection or through an infusion pump should not be used in pregnant women for prevention or prolonged (beyond 48-72 hours) treatment of preterm labor due to the potential for serious maternal heart problems and death.